Send to

Choose Destination
Oncoimmunology. 2013 May 1;2(5):e24212.

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.

Author information

INSERM; UMR892; Nantes, France ; CNRS; UMR6299; Nantes, France ; Université de Nantes; Nantes, France.


Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.


cytotoxic CD8+ T cell; measles virus vaccine; myeloid DC; oncolytic virus; plasmacytoid DC; tumor antigen

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center